核磁共振成像对良性前列腺增生组织成分的预测研究

康健, 管雯斌, 朱自强, 等. 核磁共振成像对良性前列腺增生组织成分的预测研究[J]. 临床泌尿外科杂志, 2020, 35(5): 367-370. doi: 10.13201/j.issn.1001-1420.2020.05.008
引用本文: 康健, 管雯斌, 朱自强, 等. 核磁共振成像对良性前列腺增生组织成分的预测研究[J]. 临床泌尿外科杂志, 2020, 35(5): 367-370. doi: 10.13201/j.issn.1001-1420.2020.05.008
KANG Jian, GUAN Wenbin, ZHU Ziqiang, et al. Predictive study on magnetic resonance imaging on tissue composition of benign prostatic hyperplasia[J]. J Clin Urol, 2020, 35(5): 367-370. doi: 10.13201/j.issn.1001-1420.2020.05.008
Citation: KANG Jian, GUAN Wenbin, ZHU Ziqiang, et al. Predictive study on magnetic resonance imaging on tissue composition of benign prostatic hyperplasia[J]. J Clin Urol, 2020, 35(5): 367-370. doi: 10.13201/j.issn.1001-1420.2020.05.008

核磁共振成像对良性前列腺增生组织成分的预测研究

详细信息
    通讯作者: 康健,E-mail:kangjian01@xinhuamed.com.cn
  • 中图分类号: R697

Predictive study on magnetic resonance imaging on tissue composition of benign prostatic hyperplasia

More Information
  • 目的:研究核磁共振成像(MRI)与良性前列腺增生(BPH)组织学成分的关系。方法:选取43例前列腺穿刺患者(均确认为BPH),穿刺前行核磁共振检查。穿刺标本进行腺体百分比测算,并记录各穿刺点的影像学信号强度,进行差异性分析。利用IMAGE J软件对MRI图像进行分析,判断腺体成分比,并与前列腺体积(TPV)、前列腺特异性抗原(PSA)、国际前列腺症状评分(IPSS)、残余尿量(RUV)等临床数据进行相关性分析。结果:腺瘤组、混合组、间质组在穿刺点/外周带信号比上存在显著性差异,提示腺体成分表现出较高的信号比而间质成分信号比较低。影像学图片中腺体成分比与PSA、TPV存在正相关性,与IPSS评分和RUV无明显相关性。结论:通过MRI检查,可以在临床上通过无创的方法,来判断增生部分的腺体比例,为治疗用药和决策提供帮助。
  • 加载中
  • [1]

    Kaplan SA,O'Neill E,Lowe R,et al.Prevalence of Low Testosterone in Aging Men With Benign Prostatic Hyperplasia:Data From the Proscar Long-term Efficacy and Safety Study(PLESS)[J].Aging Male,2013,16(2):48-51.

    [2]

    Liu Q,Zhu Y,Liu J,et al.Ultrasound Image Features of Intravesical Prostatic Protrusion Indicated Failure of Medication Therapy of Finasteride and Doxazosin in Patients With Benign Prostatic Hyperplasia(LUTS/BPH)[J].Int Urol Nephrol,2017,49(3):399-404.

    [3]

    张帆,左强,黄毅,等.核磁共振与超声融合成像引导下前列腺靶向穿刺对Gleason评分 ≥ 7分前列腺癌检出的临床意义[J].中国男科学杂志,2018,32(3):32-36.

    [4]

    Kim EH,Vemana G,Johnson MH,et al.Magnetic resonance imaging-targeted vs.conventional transrectal ultrasound-guided prostate biopsy:single-institution,matched cohort comparison[J].Urol Oncol,2015,33(3):109.e1-e 6.

    [5]

    夏同礼,杨新宇,那彦群.良性前列腺增生的组织病理及临床意义[J].中华医学杂志,2004,84(1):29-31.

    [6]

    Fukuta F,Masumori N,Mori M,et al.Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study[J].BJU Int,2012,110(7):1023-1029.

    [7]

    Isen K,Sinik Z,Alkibay T,et al.Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia[J].Int J Urol,2001,8(2):42-48.

    [8]

    McNeal J.Pathology of Benign Prostatic Hyperplasia.Insight into Etiology[M]//Lepor H,Walsh PC,eds.The Urologic Clinics of North America.17th ed.WB Saunders Company:Philadelphia,1990:477-486.

    [9]

    Kim CK,Park BK,Han JJ,et al.Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones:preliminary results[J].J Comput Assist Tomogr,2007,31(3):449-454.

    [10]

    Kyoda Y,Ichihara K,Hashimoto K,et al.Sustained density of neuroendocrine cells with aging precedes development of prostatic hyperplasia in spontaneously hypertensive rats[J].BMC Urol,2019,19(1):91-94.

  • 加载中
计量
  • 文章访问数:  453
  • PDF下载数:  587
  • 施引文献:  0
出版历程
收稿日期:  2020-02-20

目录